Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Magnes

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
The Pharmacogenomics Journal|July 19, 2017
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabT Magnes, T Melchardt, C Hufnagl, et al.
The Pharmacogenomics Journal|January 20, 2019
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabT Magnes, T Melchardt, C Hufnagl, et al.
ESMO Open|January 5, 2021
Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrenceT Magnes, S Wagner, A R Thorner, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
The Pharmacogenomics Journal|July 19, 2017
The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabT Magnes, T Melchardt, C Hufnagl, et al.
The Pharmacogenomics Journal|January 20, 2019
Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximabT Magnes, T Melchardt, C Hufnagl, et al.
ESMO Open|January 5, 2021
Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrenceT Magnes, S Wagner, A R Thorner, et al.
Pageof 1